SiRNA silencing of genes expressed in cancer
US8598333B2 · kind B2 · utility
21Cited by
40References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2007 |
| Grant date | Dec 3, 2013 |
| Priority date | — |
| Expiry date | Apr 20, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2982
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.